Reported 2 days ago
Billionaire Ken Griffin's Citadel has significantly reduced its shares of Palantir, which has seen a dramatic increase of 945% since late 2022, while launching a fresh position in Summit Therapeutics. Analysts predict Summit's stock could soar 139%, buoyed by promising developments in its lung cancer treatment, ivonescimab. Despite the potential for growth, cautious investors warn against the high risks associated with investing in a company without existing products.
Source: YAHOO